Toulon - CHI

The trials here

What the 4 trials at this site are about, from their registry records.

Conditions

• Lung cancer4 trials
• Mesothelioma1 trial
• Neuroendocrine tumours1 trial

Phase

• Phase 22 trials
• Phase 31 trial

Status

• Recruiting3 trials
• Completed1 trial

Lead sponsor

• Intergroupe Francophone de Cancerologie Thoracique4 trials

Running trials

• Recruiting

  Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma

  NCT07234058· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source

  Contact: Dr Clarisse AUDIGIER-VALETTE

• Recruiting

  Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

  NCT06937905· Phase 3· Intergroupe Francophone de Cancerologie Thoracique· Source

  Contact: Clarisse AUDIGIER-VALETTE

• Recruiting

  A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

  NCT06053099· Intergroupe Francophone de Cancerologie Thoracique· Source

  Contact: Clarisse AUDIGIER-VALETTE

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer3 recruiting
• Mesothelioma1 recruiting
• Neuroendocrine tumours1 recruiting

Closed trials

• Completed

  Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

  NCT04111705· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source